Safety and Efficacy Study of Phyllanthus niruri 6C in Adults with Grade 2 Fatty Liver Disease

A Prospective Single-Arm Interventional Study To Assess The Safety And Efficacy Of Phyllanthus Niruri 6C In Patients With Grade 2 Fatty Liver - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/12/099672

Enrollment

Registered

2025-12-22

Start date

Unknown

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified

Interventions

Intervention1: Phyllanthus niruri 6c: Phyllanthus niruri commonly known as Bhumi Amla has been traditionally used for its hepatoprotective and antioxidant and anti inflammatory properties Medicine wil

Eligibility

Inclusion criteria

Inclusion criteria: Patients in the age group of 18 to 60 years Diagnosed cases of grade 2 fatty liver disease confirmed by ultrasonography

Exclusion criteria

Exclusion criteria: Patients diagnosed with grade 1and grade 3 fatty liver disease or cirrhosis of liver Patients with chronic kidney disease cholecystitis hepatic malignancy or any other serious systemic illness Patients who are already on conventional hepatoprotective agents or nephrotoxic drugs Patients with uncontrolled diabetes mellitus or hypertension Pregnant or lactating women

Design outcomes

Primary

Measure	Time frame
Occurrence of any adverse drug reactions assessed throughout the study period using the ADR Probability scale Change in liver function test specifically ALT Levels Change in renal function parameters specifically serum creatinine and ureaTimepoint: baseline 3rd month and 6th month	—

Secondary

Measure	Time frame
Changes in ultrasonographic grading of fatty liverTimepoint: baseline 3rd month 6th month	—

Countries

India

Contacts

Public ContactDR Koppineedi Lakshmi Prasanthi

JIMS Homoeopathic Medical College and Hospital

samarchatterjeee01@gmail.com8250798221

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026